Share on LinkedInShare on LinkedIn

ARTICLE · 04 SEPTEMBER 2019

Recent Developments In Patent Law: Non-Obviousness Of Pharmaceutical Formulations

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

The development of pharmaceutical products is often expensive and unpredictable. Researchers investing the time and resources to develop a novel and non-obvious advancement over the art are rewarded with patent protection

United StatesIntellectual Property

The development of pharmaceutical products is often expensive and unpredictable. Researchers investing the time and resources to develop a novel and non-obvious advancement over the art are rewarded with patent protection. It is therefore important to understand the framework applied by U.S. courts to determine whether an advancement is non-obvious, and therefore patentable.

This article examines three recent Federal Circuit cases—Endo Pharmaceuticals Solutions, Inc. v. Custopharm Inc., Mylan Pharmaceuticals Inc. v. Research Corporation Technologies, Inc., and Endo Pharmaceuticals Inc. v. Actavis LLC, demonstrating how chemical and pharmaceutical formulation technology is highly complex and that the unpredictability present in drug development supports the non-obviousness of pharmaceutical patent claims.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from